Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Epigenetic modifying enzymes such as histone deacetylases (HDACs), p300, and PRMT1 are recruited by AML1/ETO, the pathogenic protein for t(8;21) acute myeloid leukemia (AML), providing a strong molecular rationale for targeting these enzymes to treat this disease. Although early phase clinical asses...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bots, Michael, Verbrugge, Inge, Martin, Benjamin P., Salmon, Jessica M., Ghisi, Margherita, Baker, Adele, Stanley, Kym, Shortt, Jake, Ossenkoppele, Gert J., Zuber, Johannes, Rappaport, Amy R., Atadja, Peter, Lowe, Scott W., Johnstone, Ricky W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2014
Konular:
Myeloid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3938147/
https://ncbi.nlm.nih.gov/pubmed/24415537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-03-488114
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller